<DOC>
	<DOCNO>NCT02151448</DOCNO>
	<brief_summary>This trial determine safest dose triple combination ( chemokine modulatory regimen CKM ) celecoxib , interferon alfa ( IFN ) , rintatolimod give DC vaccine treatment peritoneal surface malignancy standard care surgery . The first phase study determine safest dose IFN give combination celecoxib rintatolimod along DC vaccine . The dos celecoxib ( 400 mg ) rintatolimod ( 200 mg ) consistent dose IFN increase ( 5 , 10 , 20 MU/m2 ) participant enrol trial . The high dose IFN combination celecoxib rintatolimod use next phase clinical trial . After surgery , participant receive 2 cycle investigational treatment . The second phase study test investigational treatment effect peritoneal surface malignancy . The dos combination determine first phase use phase clinical trial . After surgery , participant receive 2 cycle investigational treatment , follow standard chemotherapy determine oncologist , 2 cycle investigational treatment .</brief_summary>
	<brief_title>αDC1 Vaccine + Chemokine Modulatory Regimen ( CKM ) Adjuvant Treatment Peritoneal Surface Malignancies</brief_title>
	<detailed_description>This trial evaluate safety effectiveness autologous alpha-type-1 polarize dendritic cell ( alpha-DC1 ) vaccine ( patient ' autologous alpha-DC1s load autologous tumor material ) , combine systemic chemokine modulation regimen [ CKM ; intravenous rintatolimod ( TLR3 ligand , derivative Poly-I : C ) + intravenous interferon-alfa + oral celecoxib ] adjuvant therapy , cytoreductive surgery ( CRS ) hyperthermic intraperitoneal chemotherapy ( HIPEC ) , patient peritoneal surface malignancy ( PSM ) , include limited malignant peritoneal mesothelioma peritoneal carcinomatosis ( PC ) appendiceal colorectal origin . All patient judge peritoneal surface malignancy consider able cytoreduced Peritoneal Cancer Index ( PCI ) Completeness Cytoreduction ( CC ) score 1 less undergo CRS + HIPEC . Postoperative immunotherapy start least 4 week CRS + HIPEC . Immunotherapy regimen include four cycle intranodal ( 3M cell ) intradermal ( 3M cell ) αDC1 vaccine . Each booster αDC1 vaccine dose ( treatment cycle 2-4 ) follow 4-days systemic CKM , start day vaccination ( IFNα [ dose-escalation : 5-20 MU/m2 ] , intravenous [ IV ] , day 4 day ; rintatolimod [ short-half-life TLR3 ligand ] 200 mg intravenous [ IV ] , Wednesday Friday CKM regimen ; celecoxib 200 mg , orally , twice day 4 day ) . In order avoid overlap experimental immunotherapy potential adjuvant chemotherapy ( clinically indicate part standard care subset patient ) , experimental treatment interrupt cycle 1 2 , allow adjuvant chemotherapy do patient 's clinical care , part research study . Whenever clinically indicate part standard care , adjuvant chemotherapy may start least 5 day completion 2nd cycle immunotherapy ( first booster vaccine plus first CKM ) . The 3rd cycle immunotherapy may start least 5 day completion chemotherapy .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>poly ( I ) .poly ( c12 , U )</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Patients histologically confirm peritoneal surface malignancy , include limited malignant peritoneal mesothelioma peritoneal carcinomatosis ( PC ) presume appendiceal colorectal primary tumor . Most patient receive extensive prior treatment , due recurrent nature PC . Prior therapy involve previous CRS , local systemic chemotherapy . None prior treatment disqualifies patient receive protocolmandated experimental treatment . Patients must deem able undergo optimal cytoreductive surgery ( CRS ) define CCscore 0 1 base imaging . Cytoreduction define burden residual disease nodule leave end surgery ( CC0 : visible disease ; CC1 : residual tumor nodule ≤ 2.5 mm size ; CC2 : residual tumor nodule 2.5 mm 2.5 cm size ; CC3 : residual tumor nodule &gt; 2.5 cm size ) . Patients may enrol study regardless prior chemotherapy regimens An ECOG performance status 0 , 1 2 Age equal 18 year old Patients must able understand willing sign write informed consent document Able swallow pill Must normal organ marrow function define : Platelet ≥ 75,000/µL Hemoglobin ≥ 9.0 g/dL Hematocrit ≥ 27.0 % Absolute Neutrophil Count ( ANC ) ≥ 1500/µL WBC &gt; 2000/mm3 Creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) , OR Creatinine clearance ≥ 50 mL/min/1.73 m2 patient creatinine level great 1.5 x ULN Total bilirubin ≤ 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN Patients systemic immunosuppressive agent , include steroid . Patients able removed immunosuppressive least 3 week prior first vaccine consider eligible . Patients active autoimmune disease history transplantation . Patients indolent chronic autoimmune disease require steroid treatment consider eligible . Patients pregnant nursing Patients experience cardiac event ( acute coronary syndrome , myocardial infarction , ischemia ) within 3 month prior accrual Patients New York Heart Association classification III IV Prior allergic reaction hypersensitivity celecoxib NSAIDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>